Table 2.

Summary of randomized phase II/III studies comparing first-line anti-EGFR versus anti-VEGF antibodies in combination with chemotherapy for the treatment of advanced colorectal cancer

	RAS-WT
	n	OS	ORR
FIRE-3 (n = 592 [35]
FOLFIRI-cetuximab	205	33.1 months	65%
FOLFIRI-bevacizumab	202	25.6 months	60%
P value		P = .011	P = 0.032
PEAK (n = 285) [36]
FOLFOX-panitumumab	88	41.3 months	63.6%
FOLFOX-bevacizumab	82	28.9 months	60.5%
P value		P = .058	–
CALGB/SWOG 80405 (n = 526) [37]
Cetuximab + FOLFIRI or FOLFOX-6	270	32.0 months	68.8%
Bevacizumab + FOLFIRI or FOLFOX-6	256	31.2 months	56%
P value		P = .40	P < .01